Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

TransCelerate BioPharma

- PMLiVE

Morphosys’ Darzalex patent challenge hits a hurdle

Genmab and J&J's myeloma drug is a blockbuster

- PMLiVE

J&J earnings top expectations, but feels the squeeze in US

Blockbuster Xarelto declines 14% due to US competition

- PMLiVE

Merck’s backing of NGM Bio yields NASH drug deal

Drug has potential in diabetes treatment as well

- PMLiVE

Blow for J&J as court refuses to overturn talc verdict

Reuters and company at loggerheads over veracity of claims

- PMLiVE

J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial

The majority of patients on Tremfya achieved at least a 90% improvement from PASI score

- PMLiVE

Merck exec steps down, two takes his place

Head of global human health Adam Schechter will transition to CEO advisor

- PMLiVE

Dutch biotech Argenx claims $1.8bn licensing deal with J&J

Deal centres around blood cancer candidate cusatuzumab

- PMLiVE

MSD claims EU approval for two HIV products

Company battles back against dominant Gilead and GSK

- PMLiVE

Generic threat looms to J&J’s blockbuster Zytiga in US

Impact could also be felt by Pfizer

- PMLiVE

Keytruda hits survival targets in first-line kidney cancer

New data presented at ESMO congress

- PMLiVE

Merck & Co picks Nike exec to be digital transformation leader

Cyber-security and customer focus will be key issues

- PMLiVE

Janssen submits esketamine in Europe for treatment resistant depression

Fast-acting drug would be first new treatment for refractory disease in 50 years

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links